News

Takeda applied for this subsidy in February to expand production capacity for pandemic influenza vaccines at its Hikari Plant (Hikari City, Yamaguchi Prefecture). In return for the subsidy,

The CHMP positive opinion follows recent US FDA approval of the drug for treatment of and reduction in the risk of recurrent DVT and PE. Both DVT and

The patent, which is the company’s first specifically targeting neurological conditions, is granted for the US market and is valid until 2022. The company said that the claims

The multicenter, double-blind, randomized, controlled Phase IIIb trial compares a single dose of Dalvance with the once-weekly dosage regimen of Dalvance in adult patients with ABSSSI. In the

Recently, a double-blind, placebo-controlled, multicenter Phase II trial of three doses of GED-0301 in 166 patients with active Crohn’s disease has been completed. Based on the data, which

Under the deal, Agendia’s oncology biomarker technology will be used in the evaluation of new pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials. Agendia president and

The drug is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis as well as for the management of acute pain

The deal, which is designed to leverage the expertise and experience from both the companies to optimize Biogen Idec’s clinical development processes, is structured to increase clinical trial

Under terms of the agreement, TEOXANE will become the exclusive licensor and distributor of ALPHAEON’s advanced neuromodulator, EVOSYAL, across the EU, Central Europe, Russia and South Africa. The